Sort   by:  
 Page size 
UnknownPrediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival.
Not available
S-EPMC5012662 | biostudies-literature
UnknownNut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance).
Not available
S-EPMC5891130 | biostudies-literature
GenomicsNovartis-Cattolica UFM collaboration Data Access Committee
Data Access Committee EGAC00001000512
EGAC00001000512 | EGA
Genomicsena-DATASET-NIBR-04-08-2016-14:28:22:169-118 - samples
Exome sequencing reads of two UFM individuals and their family members (totally 11 individuals) belonging to two different Fragile X families. Alignment files in BAM format are provided.
EGAD00001002276 | EGA
GenomicsExome-sequencing of two UFM individuals and their Fragile X family members.
Fragile X syndrome (FXS) is a monogenic neurodevelopmental disease often caused by a CGG triplet expansion in the 5’UTR of the FMR1 gene, which results in DNA methylation of the FMR1 promoter and its transcriptional silencing. Exceptional healthy individuals named "unmethylated full mutation (UFM)" ...
EGAS00001001737 | EGA
UnknownExtracellular serine controls epidermal stem cell fate and tumour initiation.
Not available
S-EPMC7343604 | biostudies-literature
UnknownPredicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).
Not available
S-EPMC5789809 | biostudies-literature
GenomicsWhole Genome Scan for Pancreatic Cancer Risk in the Pancreatic Cancer Cohort Consortium and Pancreatic Cancer Case-Control Consortium (PanScan)

Within the framework of the NCI-sponsored Cohort Consortium, investigators from 12 prospective epidemiologic cohorts formed the Pancreatic Cancer Cohort Consortium in 2006. This study, also known as "PanScan", is funded by the National Cancer Institute (NCI) and involves conducting a genome-w...

phs000206.v3.p2 | EGA
UnknownThe major genetic determinants of HIV-1 control affect HLA class I peptide presentation.
Not available
S-EPMC3235490 | biostudies-literature
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
Sort   by:  
 Page size